NICE
NICE backs atogepant for acute migraine treatment
June 12, 2026NICE, atogepant, migraine treatment
NICE has issued Final Draft Guidance recommending AbbVie’s AQUIPTA (atogepant) as an option for the acute treatment of migraine, with …
NICE recommends sotatercept for pulmonary arterial hypertension
May 20, 2026NICE, Winrevair, pulmonary arterial hypertension, sotatercept
The National Institute for Health and Care Excellence (NICE) has recommended Winrevair (sotatercept) as a treatment option for adults with …
Digital mental health technologies – a valuable tool in supporting people with depression and anxiety
January 29, 2026Medical Communications MHRA, NHS, NICE, Wellcome, digital technologies, medical communications, mental health
The potential benefits of digital mental health technology for managing depression, anxiety and stress, together with other forms of care, …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
September 23, 2025Research and Development HIV/AIDS, Hepatology, NHS, NICE, Oncology, Takeda, combination therapy, oncology
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment landscape and the impact of …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
May 22, 2025Market Access, Research and Development Haematology, Hympavzi, NHS, NICE, Pfizer, haemophilia B, marstacimab
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final …
Dual immunotherapy for bowel cancer now available under NHS
April 23, 2025Research and Development Bristol Myer Squibb, MHRA, NICE, Oncology, bowel cancer, colorectal cancer, immunotherapy
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in the UK by the Medicines …
Takeda announces launch of Framework to help support patient access to life-extending combination treatments
February 25, 2025Business Services Cancer, HIV/AIDS, Immunology, NHS, NICE, Oncology, Takeda, VPAG, patient access
The Conceptual Implementation Framework outlines critical points within the UK healthcare access ecosystem to help improve the introduction of combination …
NICE recommendation for KORSERDU®▼ (elacestrant) marks ‘step-change’ in the treatment of ESR1-mutated metastatic breast cancer
December 19, 2024ESR1, Menari Group, NICE, breast cancer, drug
Elacestrant is the first tailored treatment for certain people with oestrogen receptor (ER)-positive HER2-negative locally advanced and metastatic breast cancer …
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
December 10, 2024Mounjaro, NICE, lilly, weight-loss
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute for Health and Care Excellence …
The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis
August 29, 2024Research and Development AbbVie, Crohns, Gastrointestinal tract, Immunology, NICE, approval, ulcerative colitis
The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England or Wales with moderately or …
NICE recommends digital tech for ADHD diagnosis in children and young people
July 16, 2024Medical Communications ADHD, Diagnostics, NICE
The National Institute for Health and Care Excellence (NICE) has announced that its diagnostics advisory committee has recommended the QbTest …
NICE recommends migraine treatment for NHS use
April 11, 2024Medical Communications NHS, NICE, Neurology, migraine
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s Aquipta (atogepant) as an option …
GSK’s Jemperli recommended by NICE for endometrial cancer treatment
March 5, 2024Medical Communications GSK, Jemperli, NICE, Oncology, endometrial cancer
GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of Jemperli (dostarlimab) …
NICE recommends SC treatment of AbbVie’s Tepkinly for patients with DLBCL
February 1, 2024Medical Communications AbbVie, DLBCL, NICE, Oncology, lymphoma
AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended Tepkinly (epcoritamab) as a treatment …
NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19
January 12, 2024Medical Communications COVID-19, Infections and infestations, NICE
The National Institute for Health and Care Excellence (NICE) has announced that it has expanded the guidance around which patients …
Latest content
FibroFind appoints Lee Borthwick as CEO
